安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Regulus - Wikipedia
Regulus is the brightest object in the constellation Leo and one of the brightest stars in the night sky It has the Bayer designation designated α Leonis, which is Latinized to Alpha Leonis, and abbreviated Alpha Leo or α Leo
- Regulus Therapeutics Enters into Agreement to be Acquired by Novartis . . .
SAN DIEGO, April 30, 2025 PRNewswire -- Regulus Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirect
- Regulus Therapeutics
Our pipeline programs target kidney diseases of high unmet need, including ADPKD We are targeting the underlying biology of these diseases with a novel and potentially powerful approach: MicroRNA-based therapeutics News
- Novartis announces commencement of tender offer to acquire Regulus . . .
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc , a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0 001 per share (the “Shares”), of Regulus Therapeutics Inc , a Delaware corporation (“Regulus”), in exchange for (i
- Novartis grabs kidney drug developer Regulus in $1. 7bn deal
Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could
- Regulus Therapeutics Inc. (RGLS) - Yahoo Finance
Regulus Therapeutics Inc , a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States
- Regulus Therapeutics (NASDAQ:RGLS) Sees Large Volume Increase - MarketBeat
According to data from MarketBeat com, Regulus Therapeutics presently has a consensus rating of "Hold" and an average target price of $8 50 View Our Latest Report on Regulus Therapeutics Regulus Therapeutics Trading Down 3 8% The firm's fifty day moving average is $6 53 and its 200 day moving average is $3 18
- Novartis to acquire Regulus Therapeutics and farabursen, an . . .
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics
|
|
|